<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Maia Biotechnology, Inc. — News on 6ix</title>
<link>https://6ix.com/company/maia-biotechnology-inc</link>
<description>Latest news and press releases for Maia Biotechnology, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 16 Apr 2026 13:20:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/maia-biotechnology-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d7685551cc36e47533b949.webp</url>
<title>Maia Biotechnology, Inc.</title>
<link>https://6ix.com/company/maia-biotechnology-inc</link>
</image>
<item>
<title>MAIA Biotechnology Activates First U.S. Site for Ongoing International Phase 2 Expansion Trial of Novel Telomere Targeting Treatment Targeting Advanced Non-Small Cell Lung Cancer</title>
<link>https://6ix.com/company/maia-biotechnology-inc/news/maia-biotechnology-activates-first-us-site-for-ongoing-international-phase-2-expansion-trial-of-novel-telomere-targeting-treatment-targeting-advanced-non-small-cell-lung-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/maia-biotechnology-inc/news/maia-biotechnology-activates-first-us-site-for-ongoing-international-phase-2-expansion-trial-of-novel-telomere-targeting-treatment-targeting-advanced-non-small-cell-lung-cancer</guid>
<pubDate>Thu, 16 Apr 2026 13:20:00 GMT</pubDate>
<description>Exceptional measures of efficacy observed in THIO-101 Phase 2 trial to date include disease control, response rates, and survival data well above standard of care benchmarks 50,000 advanced NSCLC diagnoses in the U.S. annually CHICAGO, April 16, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that it has activated the first U.S. cl</description>
</item>
<item>
<title>MAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Anticancer Therapy</title>
<link>https://6ix.com/company/maia-biotechnology-inc/news/maia-biotechnology-expects-recent-dollar33-million-capital-raise-to-fully-fund-ongoing-pivotal-phase-3-trial-of-novel-telomere-targeting-anticancer-therapy</link>
<guid isPermaLink="true">https://6ix.com/company/maia-biotechnology-inc/news/maia-biotechnology-expects-recent-dollar33-million-capital-raise-to-fully-fund-ongoing-pivotal-phase-3-trial-of-novel-telomere-targeting-anticancer-therapy</guid>
<pubDate>Wed, 08 Apr 2026 13:00:00 GMT</pubDate>
<description>Strong participation in recent $33 million common stock offering highlights investor confidence in late-stage clinical momentum and commercial potential Statistical assessments point to high probability of technical successin Phase 3 full approval trial FDA granted Fast Track designation for dual mechanism therapy as a treatment for non-small cell lung cancer (NSCLC) CHICAGO, April 08, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-sta</description>
</item>
<item>
<title>MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer</title>
<link>https://6ix.com/company/maia-biotechnology-inc/news/maia-biotechnology-reports-overall-survival-exceeding-two-years-for-eight-patients-in-ongoing-phase-2-clinical-trial-in-non-small-cell-lung-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/maia-biotechnology-inc/news/maia-biotechnology-reports-overall-survival-exceeding-two-years-for-eight-patients-in-ongoing-phase-2-clinical-trial-in-non-small-cell-lung-cancer</guid>
<pubDate>Tue, 31 Mar 2026 13:15:00 GMT</pubDate>
<description>Potential breakthrough therapeutic targets $50B+ global immunotherapy market1 CHICAGO, March 31, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced highlights from a poster presented on March 27, 2026, at the European Lung Cancer Congress 2026 (ELCC), a premier thoracic oncology forum held March 25-28, 2026, in Copenhagen, Denmark. MA</description>
</item>
<item>
<title>MAIA Biotechnology Announces Closing of $30 Million Underwritten Public Offering of Common Stock</title>
<link>https://6ix.com/company/maia-biotechnology-inc/news/maia-biotechnology-announces-closing-of-dollar30-million-underwritten-public-offering-of-common-stock-33</link>
<guid isPermaLink="true">https://6ix.com/company/maia-biotechnology-inc/news/maia-biotechnology-announces-closing-of-dollar30-million-underwritten-public-offering-of-common-stock-33</guid>
<pubDate>Wed, 04 Mar 2026 21:00:00 GMT</pubDate>
<description>Financing included participation by healthcare-dedicated investors alongsideexisting shareholders CHICAGO, IL, March 04, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the closing of its previously announced underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $1.50 per share for aggregate gros</description>
</item>
<item>
<title>MAIA Biotechnology Announces Pricing of $30 Million Underwritten Public Offering of Common Stock</title>
<link>https://6ix.com/company/maia-biotechnology-inc/news/maia-biotechnology-announces-pricing-of-dollar30-million-underwritten-public-offering-of-common-stock</link>
<guid isPermaLink="true">https://6ix.com/company/maia-biotechnology-inc/news/maia-biotechnology-announces-pricing-of-dollar30-million-underwritten-public-offering-of-common-stock</guid>
<pubDate>Tue, 03 Mar 2026 03:45:00 GMT</pubDate>
<description>Financing included participation by healthcare-dedicated investors alongsideexisting shareholders CHICAGO, IL, March 02, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the pricing of its underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $1.50 per share for aggregate gross proceeds of $30 mil</description>
</item>
<item>
<title>MAIA Biotechnology Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants</title>
<link>https://6ix.com/company/maia-biotechnology-inc/news/maia-biotechnology-announces-proposed-underwritten-public-offering-of-common-stock-and-pre-funded-warrants</link>
<guid isPermaLink="true">https://6ix.com/company/maia-biotechnology-inc/news/maia-biotechnology-announces-proposed-underwritten-public-offering-of-common-stock-and-pre-funded-warrants</guid>
<pubDate>Mon, 02 Mar 2026 22:00:00 GMT</pubDate>
<description>CHICAGO, IL, March 02, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All of the shares of common stock and pre-funded warrants to be sold in this</description>
</item>
<item>
<title>MAIA Biotechnology’s Phase 3 Momentum Demonstrates Potential Breakthrough Anticancer Opportunity in $50 Billion Immunotherapy Market</title>
<link>https://6ix.com/company/maia-biotechnology-inc/news/maia-biotechnologys-phase-3-momentum-demonstrates-potential-breakthrough-anticancer-opportunity-in-dollar50-billion-immunotherapy-market</link>
<guid isPermaLink="true">https://6ix.com/company/maia-biotechnology-inc/news/maia-biotechnologys-phase-3-momentum-demonstrates-potential-breakthrough-anticancer-opportunity-in-dollar50-billion-immunotherapy-market</guid>
<pubDate>Tue, 24 Feb 2026 13:45:00 GMT</pubDate>
<description>Ongoing Phase 3 full approval clinical trial of ateganosine holds high probability of technical success for interim and full analysis FDA Fast Track designation offers clear pathway for ateganosine as third-line therapy for non-small cell lung cancer (NSCLC) First and only direct telomere-targeting anticancer agent in clinical development anywhere MAIA CEO details development pipeline in letter to shareholders CHICAGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MA</description>
</item>
<item>
<title>MAIA Biotechnology Advances Ateganosine Cancer Treatment Program, Outlines Targeted 2026 Clinical Milestones and Growth Momentum</title>
<link>https://6ix.com/company/maia-biotechnology-inc/news/maia-biotechnology-advances-ateganosine-cancer-treatment-program-outlines-targeted-2026-clinical-milestones-and-growth-momentum</link>
<guid isPermaLink="true">https://6ix.com/company/maia-biotechnology-inc/news/maia-biotechnology-advances-ateganosine-cancer-treatment-program-outlines-targeted-2026-clinical-milestones-and-growth-momentum</guid>
<pubDate>Tue, 20 Jan 2026 15:15:00 GMT</pubDate>
<description>High probability of technical success in pivotal Phase 3 trial based on unmatched efficacy data for third-line non-small cell lung cancer (NSCLC) treatment FDA’s Fast Track designation for ateganosine in NSCLC advances concurrent Phase 2 expansion and Phase 3 trials along strategic regulatory pathways Strong momentum toward goal of early commercial approval Potential breakthrough therapeutic for estimated $50+ billion global immunotherapy market; first and only telomere-targeting anticancer agen</description>
</item>
<item>
<title>MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings</title>
<link>https://6ix.com/company/maia-biotechnology-inc/news/maia-biotechnology-board-members-continue-to-participate-in-private-placement-financings</link>
<guid isPermaLink="true">https://6ix.com/company/maia-biotechnology-inc/news/maia-biotechnology-board-members-continue-to-participate-in-private-placement-financings</guid>
<pubDate>Wed, 24 Dec 2025 13:01:00 GMT</pubDate>
<description>Purchases reflect strong confidence in the scientific differentiation and commercial potential of ateganosine CHICAGO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that independent directors including Adelina Louie Ngar Yee and Stan V. Smith, Ph.D. purchased common stock and warrants in the recent private placement offe</description>
</item>
<item>
<title>MAIA Biotechnology Announces $1.51 Million Private Placement</title>
<link>https://6ix.com/company/maia-biotechnology-inc/news/maia-biotechnology-announces-dollar151-million-private-placement</link>
<guid isPermaLink="true">https://6ix.com/company/maia-biotechnology-inc/news/maia-biotechnology-announces-dollar151-million-private-placement</guid>
<pubDate>Tue, 16 Dec 2025 21:15:00 GMT</pubDate>
<description>CHICAGO, IL, Dec. 16, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,233,488 shares of common stock at a purchase price of $1.224 per share, in a private placement to accredited investors and a Company director. Each share of common stock is being</description>
</item>
<item>
<title>MAIA Biotechnology Announces First Patient Dosed in THIO-104 Phase 3 Pivotal Trial Evaluating Ateganosine as Third-Line Treatment for Advanced Non-Small Cell Lung Cancer</title>
<link>https://6ix.com/company/maia-biotechnology-inc/news/maia-biotechnology-announces-first-patient-dosed-in-thio-104-phase-3-pivotal-trial-evaluating-ateganosine-as-third-line-treatment-for-advanced-non-small-cell-lung-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/maia-biotechnology-inc/news/maia-biotechnology-announces-first-patient-dosed-in-thio-104-phase-3-pivotal-trial-evaluating-ateganosine-as-third-line-treatment-for-advanced-non-small-cell-lung-cancer</guid>
<pubDate>Thu, 11 Dec 2025 14:00:00 GMT</pubDate>
<description>Key milestone achieved as Company advances clinical program to full approval trial of ateganosine sequenced with a checkpoint inhibitor in comparison to chemotherapy CHICAGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the first patient has been dosed in the Company’s THIO-104 Phase 3 pivotal trial evaluating the</description>
</item>
<item>
<title>MAIA Biotechnology Announces Open Market Purchases by CEO and Directors</title>
<link>https://6ix.com/company/maia-biotechnology-inc/news/maia-biotechnology-announces-open-market-purchases-by-ceo-and-directors</link>
<guid isPermaLink="true">https://6ix.com/company/maia-biotechnology-inc/news/maia-biotechnology-announces-open-market-purchases-by-ceo-and-directors</guid>
<pubDate>Mon, 01 Dec 2025 14:17:00 GMT</pubDate>
<description>CHICAGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the CEO and certain members of the Company’s Board of Directors purchased approximately 182,445 shares of MAIA common stock at market price between November 21 and 28, 2025. The average common stock price was $1.06. Vlad Vitoc, M.D., Chairman and CEO of MAIA, pu</description>
</item>
<item>
<title>MAIA Biotechnology Highlights Ongoing Momentum of Ateganosine Clinical Program at SITC 2025</title>
<link>https://6ix.com/company/maia-biotechnology-inc/news/maia-biotechnology-highlights-ongoing-momentum-of-ateganosine-clinical-program-at-sitc-2025</link>
<guid isPermaLink="true">https://6ix.com/company/maia-biotechnology-inc/news/maia-biotechnology-highlights-ongoing-momentum-of-ateganosine-clinical-program-at-sitc-2025</guid>
<pubDate>Fri, 21 Nov 2025 14:01:00 GMT</pubDate>
<description>Company confirms 12 patients enrolled in Phase 2 THIO-101 to date as expansion trial adds new countries Posters for Phase 2 and Phase 3 clinical trials available CHICAGO , Nov. 21, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced highlights from two poster presentations delivered at SITC 2025, an annual conference hosted by the Soci</description>
</item>
<item>
<title>MAIA Biotechnology CEO Presents Telomere Targeting Efficacy at Romania’s 2025 Smart Diaspora Conference on Oncology Research and Innovation</title>
<link>https://6ix.com/company/maia-biotechnology-inc/news/maia-biotechnology-ceo-presents-telomere-targeting-efficacy-at-romanias-2025-smart-diaspora-conference-on-oncology-research-and-innovation</link>
<guid isPermaLink="true">https://6ix.com/company/maia-biotechnology-inc/news/maia-biotechnology-ceo-presents-telomere-targeting-efficacy-at-romanias-2025-smart-diaspora-conference-on-oncology-research-and-innovation</guid>
<pubDate>Thu, 20 Nov 2025 13:47:00 GMT</pubDate>
<description>Company starts enrollment in Romania for Phase 2 THIO-101 Part C study of ateganosine as a treatment for advanced non-small cell lung cancer patients CHICAGO, Nov. 20, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced a presentation by CEO Vlad Vitoc, M.D. at Smart Diaspora 2025, a conference dedicated to advancing oncology research</description>
</item>
<item>
<title>MAIA Biotechnology Presents Trial in Progress Poster at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics</title>
<link>https://6ix.com/company/maia-biotechnology-inc/news/maia-biotechnology-presents-trial-in-progress-poster-at-the-2025-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics</link>
<guid isPermaLink="true">https://6ix.com/company/maia-biotechnology-inc/news/maia-biotechnology-presents-trial-in-progress-poster-at-the-2025-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics</guid>
<pubDate>Mon, 27 Oct 2025 14:45:00 GMT</pubDate>
<description>First five patients in Part C (expansion) of THIO-101 Phase 2 clinical trial enrolled in Taiwan and Turkey CHICAGO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced its recent attendance at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The Conference, held October 22-26, 2025</description>
</item>
<item>
<title>MAIA Biotechnology Details 30-Month Patient Survival in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer</title>
<link>https://6ix.com/company/maia-biotechnology-inc/news/maia-biotechnology-details-30-month-patient-survival-in-ongoing-phase-2-clinical-trial-in-non-small-cell-lung-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/maia-biotechnology-inc/news/maia-biotechnology-details-30-month-patient-survival-in-ongoing-phase-2-clinical-trial-in-non-small-cell-lung-cancer</guid>
<pubDate>Thu, 23 Oct 2025 12:36:00 GMT</pubDate>
<description>Outstanding measure of efficacy relative to high-risk cancers with limited treatment options CHICAGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced highlights from a recent presentation at the European Society for Medical Oncology (ESMO) Congress 2025 held in Berlin, Germany. Starting October 19, 2025, MAIA showcased two</description>
</item>
<item>
<title>MAIA Biotechnology Announces $736,600 Private Placement</title>
<link>https://6ix.com/company/maia-biotechnology-inc/news/maia-biotechnology-announces-dollar736600-private-placement</link>
<guid isPermaLink="true">https://6ix.com/company/maia-biotechnology-inc/news/maia-biotechnology-announces-dollar736600-private-placement</guid>
<pubDate>Mon, 13 Oct 2025 20:20:00 GMT</pubDate>
<description>CHICAGO, IL, Oct. 13, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 603,769 shares of common stock at a purchase price of $1.22 per share, in a private placement to accredited investors. Each share of common stock is being offered together with a wa</description>
</item>
<item>
<title>MAIA Biotechnology Announces $2.25 Million Private Placement</title>
<link>https://6ix.com/company/maia-biotechnology-inc/news/maia-biotechnology-announces-dollar225-million-private-placement</link>
<guid isPermaLink="true">https://6ix.com/company/maia-biotechnology-inc/news/maia-biotechnology-announces-dollar225-million-private-placement</guid>
<pubDate>Mon, 29 Sep 2025 20:30:00 GMT</pubDate>
<description>CHICAGO, IL, Sept. 29, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,733,766 shares of common stock at a purchase price of $1.30 per share, in a private placement to accredited investors and a Company director. Each share of common stock is being</description>
</item>
<item>
<title>MAIA Biotechnology Awarded $2.3 Million Grant by National Institutes of Health for THIO-101 Phase 2 Trial of Cancer-Fighting Agent</title>
<link>https://6ix.com/company/maia-biotechnology-inc/news/maia-biotechnology-awarded-dollar23-million-grant-by-national-institutes-of-health-for-thio-101-phase-2-trial-of-cancer-fighting-agent</link>
<guid isPermaLink="true">https://6ix.com/company/maia-biotechnology-inc/news/maia-biotechnology-awarded-dollar23-million-grant-by-national-institutes-of-health-for-thio-101-phase-2-trial-of-cancer-fighting-agent</guid>
<pubDate>Wed, 24 Sep 2025 12:01:00 GMT</pubDate>
<description>THIO-101 Phase 2 trial to enroll patients in the U.S. as part of the expansion of the study in third-line treatment for advanced non-small cell lung cancer (NSCLC) CHICAGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, announced today that the National Institutes of Health (NIH) has awarded a $2.3 million grant for the expansion of its</description>
</item>
<item>
<title>MAIA Biotechnology Highlights Positive Efficacy Data from THIO-101 Phase 2 Clinical Trial in Non-Small Cell Lung Cancer</title>
<link>https://6ix.com/company/maia-biotechnology-inc/news/maia-biotechnology-highlights-positive-efficacy-data-from-thio-101-phase-2-clinical-trial-in-non-small-cell-lung-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/maia-biotechnology-inc/news/maia-biotechnology-highlights-positive-efficacy-data-from-thio-101-phase-2-clinical-trial-in-non-small-cell-lung-cancer</guid>
<pubDate>Thu, 11 Sep 2025 13:27:00 GMT</pubDate>
<description>CHICAGO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today highlighted positive efficacy data from its Phase 2 clinical trial, THIO-101, evaluating ateganosine (THIO) sequenced with the immune checkpoint inhibitor (CPI) cemiplimab (Libtayo®) in patients with advanced non-small cell lung cancer (NSCLC) who had failed two or more stand</description>
</item>
</channel>
</rss>